Beryl Drugs Ltd

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 Aug 2026. This change reflects a combination of deteriorating financial trends, mixed technical signals, and valuation considerations, despite some attractive pricing metrics. The downgrade highlights concerns over the company’s long-term growth prospects and debt servicing ability amid a challenging market environment.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reported a flat financial performance for the quarter ended June 2026, marking a notable shift from its previously positive growth trajectory. Despite a robust 29.75% increase in net sales over the last six months, the company’s overall financial trend score has declined, prompting a reassessment of its near-term prospects.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 6 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and recent financial performance, despite some lingering concerns over long-term fundamentals and profitability trends.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 July 2026. The revision reflects a combination of deteriorating technical indicators, modest financial trends, valuation considerations, and concerns over long-term quality metrics. This comprehensive analysis explores the four key parameters that triggered the downgrade and what it means for investors.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 8 July 2026. This change reflects a combination of improved technical indicators, attractive valuation metrics, positive quarterly financial results, and rising promoter confidence, despite some lingering concerns over long-term fundamentals.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a significant improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option relative to its historical averages and peer group.

Beryl Drugs Ltd., an Indore-based pharmaceutical manufacturer specialising in intravenous fluids and injectable formulations, reported a remarkable turnaround in Q4 FY26 (January-March 2026), posting net profit of ₹0.56 crores compared to a loss of ₹0.17 crores in the previous quarter. The micro-cap company, with a market capitalisation of just ₹11.00 crores, demonstrated strong sequential momentum with revenue surging 35.71% quarter-on-quarter to ₹5.13 crores, whilst operating margins expanded dramatically to 26.12% from negative territory in Q3 FY26.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s financial trend shifted from flat to positive, with key profitability metrics reaching their highest levels in recent quarters, signalling a potential inflection point for investors amid a challenging market backdrop.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 May 2026. This revision reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some valuation appeal and rising promoter confidence.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite ongoing challenges in its financial performance and valuation metrics.

Beryl Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 March 2026. This shift reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals, despite an attractive valuation. The company’s stock price has also suffered, declining 7.10% on the day of the downgrade, underscoring investor concerns.

Beryl Drugs Ltd’s share price declined to a fresh 52-week low of Rs.15.92 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and broader market indices.

Beryl Drugs Ltd’s shares declined sharply to a fresh 52-week low of Rs.16.2 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.